{"analyses":[{"ciLowerLimit":"0.451","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.878","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0061","pValueComment":"Two-sided P-value.","paramType":"Hazard Ratio (HR)","paramValue":"0.63","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"23.3","upperLimit":"33.4","value":"29.7"},{"groupId":"OG001","lowerLimit":"14.4","upperLimit":"25.5","value":"19.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"65"}],"units":"Participants"}],"description":"TSST was defined as the date of randomization to the earlier of the start date of second follow-up anti-cancer treatment or death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with germline breast cancer gene (gBRCA) mutation received oral dose of niraparib 300 milligrams (mg) once daily in 28-day cycles until disease progression.","id":"OG000","title":"gBRCA Niraparib"},{"description":"Participants with germline BRCA mutation received oral dose of placebo matching niraparib once daily in 28-day cycles until disease progression.","id":"OG001","title":"gBRCA Placebo"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat population","reportingStatus":"POSTED","timeFrame":"From the date of randomization to the start date of the second subsequent anti-cancer therapy, up to 7 years, 7 months and 4 days","title":"Time to Second Subsequent Therapy in Cohort With Germline BRCA Mutation (gBRCA)","type":"SECONDARY","unitOfMeasure":"Months"}